XOMA Royalty (XOMA) Cash from Restructuring (2016 - 2017)
XOMA Royalty's (XOMA) quarterly Cash from Restructuring came in at -$314000.0 in Q4 2017, down 108.78% year-on-year from $3.6 million in Q4 2016, and up 45.49% quarter-over-quarter from -$576000.0 in Q3 2017.
XOMA Royalty (XOMA) Cash from Restructuring (2016 - 2017) Analysis & Trends
XOMA Royalty has disclosed Cash from Restructuring across 2 years of filings, most recently posting -$314000.0 for Q4 2017.
- Cash from Restructuring for Q4 2017 came in at -$314000.0, down 108.78% year-over-year; the trailing twelve-month figure through Dec 2017 was -$3.5 million (down 210.49% YoY), and the FY2017 annual result was -$3.5 million, down 210.49% from the prior year.
- Cash from Restructuring came in at -$314000.0 for Q4 2017 at XOMA Royalty, up from -$576000.0 in the prior quarter.
- In the past five years, Cash from Restructuring ranged from a high of $3.6 million in Q4 2016 to a low of -$1.8 million in Q1 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | -314,000.00 |
| Sep 30, 2017 | -576,000.00 |
| Jun 30, 2017 | -773,000.00 |
| Mar 31, 2017 | -1.80 Mn |
| Dec 31, 2016 | 3.58 Mn |
| Sep 30, 2016 | 1,000.00 |
| Jun 30, 2016 | -120,000.00 |
| Mar 31, 2016 | -321,000.00 |